Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (41-50 of 508) with videos related to

Pageof 51
Sort By:
BMJ (Clinical Research Ed.)|May 12, 2012
Outcomes of elective induction of labour compared with expectant management: population based studySarah J Stock, Evelyn Ferguson, Andrew Duffy, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
BMJ (Clinical Research Ed.)|May 24, 2003
Stepping down inhaled corticosteroids in asthma: randomised controlled trialGillian Hawkins, Alex D McMahon, Sara Twaddle, et al.
BMC Medicine|August 18, 2010
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safetyAlan G Wade, Ian Ford, Gordon Crawford, et al.
Current Medical Research and Opinion|November 25, 2010
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term responseAlan G Wade, Gordon Crawford, Ian Ford, et al.
European Journal of Heart Failure|May 24, 2016
Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFTMichel Komajda, Luigi Tavazzi, Karl Swedberg, et al.
The New England Journal of Medicine|October 12, 2007
Long-term follow-up of the West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Chris J Packard, et al.
The American Journal of Cardiology|December 17, 2013
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)Jeffrey S Borer, Michael Böhm, Ian Ford, et al.
European Journal of Heart Failure|May 29, 2018
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysisMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
International Journal of Cardiology|February 24, 2015
Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk ModelIan Ford, Michele Robertson, Michel Komajda, et al.
Pageof 51

Showing results (41-50 of 508) with videos related to

Sort By:
Pageof 51
BMJ (Clinical Research Ed.)|May 12, 2012
Outcomes of elective induction of labour compared with expectant management: population based studySarah J Stock, Evelyn Ferguson, Andrew Duffy, et al.
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
BMJ (Clinical Research Ed.)|May 24, 2003
Stepping down inhaled corticosteroids in asthma: randomised controlled trialGillian Hawkins, Alex D McMahon, Sara Twaddle, et al.
BMC Medicine|August 18, 2010
Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safetyAlan G Wade, Ian Ford, Gordon Crawford, et al.
Current Medical Research and Opinion|November 25, 2010
Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term responseAlan G Wade, Gordon Crawford, Ian Ford, et al.
European Journal of Heart Failure|May 24, 2016
Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFTMichel Komajda, Luigi Tavazzi, Karl Swedberg, et al.
The New England Journal of Medicine|October 12, 2007
Long-term follow-up of the West of Scotland Coronary Prevention StudyIan Ford, Heather Murray, Chris J Packard, et al.
The American Journal of Cardiology|December 17, 2013
Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)Jeffrey S Borer, Michael Böhm, Ian Ford, et al.
European Journal of Heart Failure|May 29, 2018
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysisMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
International Journal of Cardiology|February 24, 2015
Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk ModelIan Ford, Michele Robertson, Michel Komajda, et al.
Pageof 51